Status:
COMPLETED
Symptoms and Clinical Signs of Hypogonadism in Testicular Cancer Survivors
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Metabolic Syndrome
Hypogonadism
Eligibility:
MALE
18-65 years
Brief Summary
The purpose of this study is to investigate the prevalence of signs and symptoms of hypogonadism in three groups of testicular cancer survivors.
Detailed Description
Recent studies have shown that metabolic syndrome is common among testicular cancer. Patients with low levels of testosterone appear to be at higher risk of metabolic syndrome. A substantial number o...
Eligibility Criteria
Inclusion
- Earlier treatment of testicular germ cell cancer
- No sign of relapse \> 1 year since latest treatment
- Testosterone \< 12 nmol/L and luteinizing hormone \> 8 IE/L OR
- Testosterone \> 12 nmol/L and LH \> 8 IE/L OR
- Testosterone and LH within their normal ranges
Exclusion
- Testosterone substitution
Key Trial Info
Start Date :
August 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT02240966
Start Date
August 1 2014
End Date
July 1 2016
Last Update
July 14 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark, 2100